Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.55 |
| ▸ | METAP1 | P53582 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.43 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.43 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30715530 | 1.00 | ACHE (0.56) | ACHECYP19A1METAP1ALDH1A1CYP3A4 | |
| SCHEMBL3587277 | 0.88 | CYP24A1 (0.55) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL5237018 | 0.83 | ACHE (0.71) | ACHECYP19A1METAP1ALDH1A1CYP3A4 | |
| SCHEMBL5237012 | 0.83 | ACHE (0.71) | ACHECYP19A1METAP1ALDH1A1CYP3A4 | |
| SCHEMBL5237022 | 0.83 | ACHE (0.71) | ACHECYP19A1METAP1ALDH1A1CYP3A4 | |
| SCHEMBL13363970 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL31040171 | 0.81 | CYP19A1 (0.59) | ACHECYP19A1METAP1ALDH1A1CYP3A4 | |
| SCHEMBL3875408 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1ALDH1A1CYP3A4 | |
| SCHEMBL6630846 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1DRD2DRD3 | |
| SCHEMBL30714800 | 0.81 | ACHE (0.56) | ACHECYP19A1METAP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117126126-A | Method for asymmetrically synthesizing adjacent halohydrin compound | 凯特立斯（深圳）科技有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-8426440-B2 | Indolymaleimide derivatives | NOVARTIS AG (CH) | 2013-04-23 | — | — | US | disclosed |
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | disclosed |
| EP-2246346-B1 | Indolylmaleimide derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-1904482-B1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2011-01-19 | — | — | EP | disclosed |
| EP-2270001-A1 | Indolylmaleimide derivatives as PKC inhibitors | Novartis AG (CH) | 2011-01-05 | — | — | EP | disclosed |
| EP-2246346-A1 | Indolylmaleimide derivatives as protein kinase inhibitors | Novartis AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | WAGNER JUERGEN | 2010-10-28 | — | — | US | disclosed |
| US-7781438-B2 | Indolylmaleimide derivatives | NOVARTIS AG (CH) | 2010-08-24 | — | — | US | disclosed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | disclosed |
| US-20080318975-A1 | Indolylmaleimide Derivatives | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1904482-A2 | INDOLYLMALEIMIDE DERIVATIVES | Novartis AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| EP-1745037-A1 | INDOLYLMALEIMIDE DERIVATIVES AS PKC INHIBITORS | Novartis AG (CH) | 2007-01-24 | — | — | EP | disclosed |
| WO-2007006533-A2 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2007-01-18 | — | — | WO | disclosed |
| WO-2005068455-A1 | INDOLYLMALEIMDE DERIVATIVES AS PKC INHIBITORS | NOVARTIS AG (CH) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273774-A1 | INDOLYMALEIMIDE DERIVATIVES | IDO1, INMT, IDO2 | ACHE 3083/4885CYP19A1 124/4885METAP1 3924/4885 |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | ACHE 2009/4885CYP19A1 4288/4885METAP1 1673/4885 |
| US-20080318975-A1 | Indolylmaleimide Derivatives | IDH3A, INMT, IDH3B | ACHE 1598/4885CYP19A1 298/4885METAP1 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.